FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending December 2009
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Financial Services Authority
GlaxoSmithKline plc received on 4 December 2009 from BlackRock, Inc a notification of interests in GlaxoSmithKline plc Ordinary shares of 25 pence each, dated on 1 December 2009. This notice is given in accordance with DTR 5.8.12.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
||||
1. Identity of the issuer or the underlying issuer |
GLAXOSMITHKLINE PLC |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
X | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
||||
An event changing the breakdown of voting rights |
||||
Other (please specify): |
||||
3. Full name of person(s) subject to the |
BlackRock, Inc |
|||
4. Full name of shareholder(s) |
||||
5. Date of the transaction and date on |
1st December 2009 |
|||
6. Date on which issuer notified: |
3rd December 2009 |
|||
7. Threshold(s) that is/are crossed or |
Holding has gone above 5% |
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of if possible using |
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
GB0009252882 |
N/A |
N/A |
N/A |
N/A |
329,124,508 |
N/A |
6.34% |
|||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to |
% of voting rights xix, xx |
|||||||||||
CFD |
N/A |
N/A |
N/A |
3,113,781 |
Nominal |
Delta |
||||||||||
0.06% |
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
332,238,289 |
6.40% |
9. Chain of controlled undertakings through which the voting rights and/or the |
|
On 1 December 2009, the Barclays Global Investors (BGI) business was acquired by BlackRock, Inc. The combined holdings of BlackRock, Inc. following this acquisition triggered this disclosure requirement BlackRock Investment Management (UK ) Limited - 332,238,289 (6.40%) |
|
Proxy Voting: |
|
10. Name of the proxy holder: |
N/A |
11. Number of voting rights proxy holder will cease |
N/A |
12. Date on which proxy holder will cease to hold |
N/A |
13. Additional information: |
BlackRock Compliance Disclosures Team |
14. Contact name: |
Stuart Watchorn |
15. Contact telephone number: |
020 7743 5741; stuart.watchorn@blackrock.com |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: December 04 2009
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc